Constitutive and IFNγ-induced activation of MHC2TA promoter type III in human melanoma cell lines is governed by separate regulatory elements within the PIII upstream regulatory region-Reference-Cited by-同舟云学术

Constitutive and IFNγ-induced activation of MHC2TA promoter type III in human melanoma cell lines is governed by separate regulatory elements within the PIII upstream regulatory region

Published:2007-03 Issue:8 Volume:44 Page:2036-2046
ISSN:0161-5890
Container-title:Molecular Immunology
language:en
Short-container-title:Molecular Immunology

Author:

van der Stoep Nienke,Quinten Edwin,Alblas Gabrielle,Plancke Aurelie,van Eggermond Marja C.J.A.,Holling Tjadine M.,van den Elsen Peter J.

Publisher

Elsevier BV

Subject

Molecular Biology,Immunology

Reference32 articles.

1. Akiyama, Y., TFSEARCH: Searching transcription factor binding sites. http://www.rwcp.or.jp/papia/.

2. Pathology and prognostic factors;Barnhill;Curr. Opin. Oncol.,1993

3. HLA-DR and 96-K antigens and intratumoral lymphocytic infiltrate in primary cutaneous melanoma as markers of tumor progression;Brogelli;Dermatologica,1990

4. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes;Chang;J. Exp. Med.,1994

5. High-efficiency transformation of mammalian cells by plasmid DNA;Chen;Mol. Cell. Biol.,1987

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ZBTB48 is a pioneer factor regulating B-cell-specific CIITA expression;2023-07-27

2. Global and context-specific transcriptional consequences of oncogenic Fbw7 mutations;eLife;2022-02-28

3. Global and context-specific transcriptional consequences of oncogenic Fbw7 mutations;2021-10-21

4. In Primitive Zebrafish, MHC Class II Expression Is Regulated by IFN-γ, IRF1, and Two Forms of CIITA;The Journal of Immunology;2020-03-18

5. Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial;OncoImmunology;2018-02-22